/SRRK
SRRK Stock - Scholar Rock Holding Corporation
Healthcare|BiotechnologyNASDAQ
$43.90+2.26%
+$0.97 (+2.26%) • Dec 19
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.92
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).74
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.95
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+12.2%upside
Target: $49.26
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SRRK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$43.46 – $44.34
TARGET (TP)$49.25
STOP LOSS$40.39
RISK/REWARD1:1.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.62
52W High$48.28
52W Low$22.71
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $33.19M | $18.82M | $15.40M |
| Gross Profit | $-1,937,000 | $-2,844,000 | $-89,851,000 | $-89,652,000 | $-58,659,000 |
| Gross Margin | N/A | N/A | -270.7% | -476.5% | -380.8% |
| Operating Income | $-252,054,000 | $-171,295,000 | $-134,370,000 | $-129,920,000 | $-86,878,000 |
| Net Income | $-246,294,000 | $-165,789,000 | $-134,502,000 | $-131,799,000 | $-86,483,000 |
| Net Margin | N/A | N/A | -405.2% | -700.5% | -561.5% |
| EPS | $-2.47 | $-1.99 | $-2.21 | $-3.59 | $-2.77 |
Company Overview
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
2
18%
Buy / Outperform
9
82%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
11 Bullish0 Neutral/Bearish
Price Targets
$39
Average Target
↓ 11.5% Downside
Now
$20
Low
$39
Average
$53
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 18th 2025 | Wolfe Research | Initiation | Outperform | $42 |
| October 9th 2025 | BofA Securities | Initiation | Buy | $53 |
| September 17th 2025 | Barclays | Initiation | Overweight | $45 |
| September 15th 2025 | Leerink Partners | Initiation | Outperform | $51 |
| August 21st 2025 | Jefferies | Resumed | Buy | $50 |
| July 30th 2025 | Raymond James | Resumed | Strong Buy | $53 |
| July 17th 2025 | Cantor Fitzgerald | Initiation | Overweight | - |
| November 26th 2024 | H.C. Wainwright | Reiterated | Buy | $50← $40 |
| October 7th 2024 | H.C. Wainwright | Reiterated | Buy | $35← $30 |
| March 28th 2024 | Raymond James | Initiation | Strong Buy | $30 |
| October 25th 2023 | Jefferies | Upgrade | Buy | $20 |
| April 3rd 2023 | Piper Sandler | Resumed | Overweight | $26 |
| September 19th 2022 | H.C. Wainwright | Resumed | Buy | $30 |
| July 12th 2022 | Truist | Initiation | Buy | $20 |
Earnings History & Surprises
SRRKBeat Rate
39%
Last 18 quarters
Avg Surprise
+1.5%
EPS vs Estimate
Beats / Misses
7/9
2 met exactly
Latest EPS
$-0.90
Q4 2025
EPS Surprise History
Q1 24
-2.0%
$-0.50vs$-0.49
Q2 24
-15.7%
$-0.59vs$-0.51
Q3 24
+1.6%
$-0.60vs$-0.61
Q4 24
-13.8%
$-0.66vs$-0.58
Q1 25
0.0%
$-0.60vs$-0.60
Q2 25
-6.3%
$-0.67vs$-0.63
Q3 25
-48.5%
$-0.98vs$-0.66
Q4 25
-7.8%
$-0.90vs$-0.84
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.86 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.84 | $-0.90 | -7.8% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.66 | $-0.98 | -48.5% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.63 | $-0.67 | -6.3% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.60 | $-0.60 | 0.0% | = MET |
Q4 2024 | Nov 12, 2024 | $-0.58 | $-0.66 | -13.8% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.61 | $-0.60 | +1.6% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.51 | $-0.59 | -15.7% | ✗ MISS |
Q1 2024 | Mar 19, 2024 | $-0.49 | $-0.50 | -2.0% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.53 | $-0.53 | 0.0% | = MET |
Q3 2023 | Aug 9, 2023 | $-0.56 | $-0.47 | +16.1% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.57 | $-0.49 | +14.0% | ✓ BEAT |
Q1 2023 | Mar 7, 2023 | $-0.58 | $-0.46 | +20.7% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.68 | $-0.55 | +19.1% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-1.03 | $-1.06 | -2.9% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.79 | $-0.21 | +73.4% | ✓ BEAT |
Q1 2022 | Mar 7, 2022 | $-1.04 | $-0.97 | +6.7% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.85 | $-1.02 | -20.0% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.78 | $-0.84 | -7.7% | ✗ MISS |
Latest News
Barclays Maintains Overweight on Scholar Rock Holding, Raises Price Target to $52
📈 PositiveBenzinga•Dec 17, 2025, 05:55 PM•Also:
Wolfe Research Initiates Coverage On Scholar Rock Holding with Outperform Rating, Announces Price Target of $42
📈 PositiveBenzinga•Nov 18, 2025, 04:59 PM
JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $47
📈 PositiveBenzinga•Nov 18, 2025, 03:44 PM
Barclays Maintains Overweight on Scholar Rock Holding, Raises Price Target to $45
📈 PositiveBenzinga•Nov 17, 2025, 02:52 PM•Also:
Scholar Rock Holding shares are trading higher. The company announced a $200 million equity offering.
➖ NeutralBenzinga•Nov 14, 2025, 02:30 PM
Scholar Rock Launches $200 Million At-The-Market Equity Offering Through Jefferies to Bolster Financial Flexibility and Support Ongoing Growth
➖ NeutralBenzinga•Nov 14, 2025, 12:54 PM•Also:
Scholar Rock Holding Q3 EPS $(0.90) Misses $(0.70) Estimate; Cash $369.6M
📉 NegativeBenzinga•Nov 14, 2025, 12:03 PM
Truist Securities Maintains Buy on Scholar Rock Holding, Lowers Price Target to $44
📈 PositiveBenzinga•Oct 20, 2025, 04:38 PM
Scholar Rock shares are trading lower after the company said the FDA classified a Novo Nordisk-owned Catalent facility as "official action indicated."
📉 NegativeBenzinga•Oct 13, 2025, 04:47 PM•Also: ,
Scholar Rock Says Novo Nordisk Informed, Following FDA Form 483 Issued To Catalent Indiana, FDA Determined Inspection Classification Of Facility Is OAI; Continue To Work Closely With Novo Nordisk, Have Requested Type A Meeting With FDA To Discuss Next Steps For Resubmitting Bla
📉 NegativeBenzinga•Oct 13, 2025, 01:38 PM•Also: ,
B of A Securities Initiates Coverage On Scholar Rock Holding with Buy Rating, Announces Price Target of $53
📈 PositiveBenzinga•Oct 9, 2025, 11:02 AM
Piper Sandler Maintains Overweight on Scholar Rock Holding, Lowers Price Target to $51
➖ NeutralBenzinga•Sep 24, 2025, 04:10 PM
Barclays Maintains Overweight on Scholar Rock Holding, Lowers Price Target to $44
➖ NeutralBenzinga•Sep 24, 2025, 12:40 PM•Also:
SRRK stock has given up its prior loss. Scholar Rock Holding shares were trading lower after the company announced that the FDA issued a Complete Response Letter for the apitegromab Biologics License Application for the treatment of patients with spinal muscular atrophy.
📉 NegativeBenzinga•Sep 23, 2025, 02:24 PM
Scholar Rock Holding shares are trading lower after the company announced that the FDA issued a Complete Response Letter for the apitegromab Biologics License Application for the treatment of patients with spinal muscular atrophy.
📉 NegativeBenzinga•Sep 23, 2025, 12:56 PM
Scholar Rock drops as FDA declines to approve lead drug
📉 NegativeSeeking Alpha•Sep 23, 2025, 11:45 AM
Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Sep 23, 2025, 11:25 AM
Scholar Rock Receives FDA Complete Response Letter For Apitegromab In Spinal Muscular Atrophy Due To Catalent Indiana Fill-Finish Facility Observations
📉 NegativeBenzinga•Sep 23, 2025, 11:04 AM•Also:
Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Sep 23, 2025, 10:55 AM
Barclays Initiates Coverage On Scholar Rock Holding with Overweight Rating, Announces Price Target of $45
📈 PositiveBenzinga•Sep 17, 2025, 10:58 AM•Also:
Frequently Asked Questions about SRRK
What is SRRK's current stock price?
Scholar Rock Holding Corporation (SRRK) is currently trading at $43.90 per share. The stock has moved +2.26% today.
What is the analyst price target for SRRK?
The average analyst price target for SRRK is $49.25, based on 1 analyst.
What sector is Scholar Rock Holding Corporation in?
Scholar Rock Holding Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SRRK's market cap?
Scholar Rock Holding Corporation has a market capitalization of $4.48 billion, making it a mid-cap company.
Does SRRK pay dividends?
No, Scholar Rock Holding Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADPT
Adaptive Biotechnologies Corporation
$17.00
Mkt Cap: $2.6B
BEAM
Beam Therapeutics Inc.
$26.57
Mkt Cap: $2.7B
CDTX
Cidara Therapeutics, Inc.
$220.80
Mkt Cap: $5.6B
IDYA
IDEAYA Biosciences, Inc.
$33.55
Mkt Cap: $2.9B
IRON
Disc Medicine, Inc.
$80.04
Mkt Cap: $3.0B
KNSA
Kiniksa Pharmaceuticals, Ltd.
$43.19
Mkt Cap: $3.2B
LEGN
Legend Biotech Corporation
$21.92
Mkt Cap: $2.0B
MLYS
Mineralys Therapeutics, Inc.
$36.83
Mkt Cap: $2.4B
XENE
Xenon Pharmaceuticals Inc.
$44.10
Mkt Cap: $3.4B
ZLAB
Zai Lab Limited
$18.04
Mkt Cap: $2.0B
Explore stocks similar to SRRK for comparison